ArticleScience advances2020
Single-dose mRNA therapy via biomaterial-mediated sequestration of overexpressed proteins.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The mRNA-Based Innovative Strategy: Progress and Challenges.Nano-micro letters · 2026Review
- Payload-Driven Design of Polymeric Carriers for Nucleic Acid Delivery: Insights from Structure-Function Relationships.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Unlock the sustained therapeutic efficacy of mRNA.Journal of controlled release : official journal of the Controlled Release Society · 2025Review
- Local delivery of TGF-β1-mRNA decreases fibrosis in osteochondral defects.Bioactive materials · 2025Article
- Gelatin methacryloyl granular scaffolds for localized mRNA delivery.Aggregate (Hoboken, N.J.) · 2024Article
- Optimized biomimetic minerals maintain activity of mRNA complexes after long term storage.Acta biomaterialia · 2024Article
- mRNA vaccines in disease prevention and treatment.Signal transduction and targeted therapy · 2023Review
- Matrices Activated with Messenger RNA.Journal of functional biomaterials · 2023Review
- Mineral coated microparticles doped with fluoride and complexed with mRNA prolong transfection in fracture healing.Frontiers in bioengineering and biotechnology · 2023Article
- Therapeutic approaches to activate the canonical Wnt pathway for bone regeneration.Journal of tissue engineering and regenerative medicine · 2022Review
- A Localized Materials-Based Strategy to Non-Virally Deliver Chondroitinase ABC mRNA Improves Hindlimb Function in a Rat Spinal Cord Injury Model.Advanced healthcare materials · 2022Article
- Gene therapy to enhance angiogenesis in chronic wounds.Molecular therapy. Nucleic acids · 2022Review
- Biomaterial-Mediated Protein Expression Induced by Peptide-mRNA Nanoparticles Embedded in Lyophilized Collagen Scaffolds.Pharmaceutics · 2022Article
- Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases.RNA biology · 2022Review
- The infinite possibilities of RNA therapeutics.Journal of industrial microbiology & biotechnology · 2021Article
- mRNA, a Revolution in Biomedicine.Pharmaceutics · 2021Review
- New insights into balancing wound healing and scarless skin repair.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Nonviral mRNA delivery is an attractive therapeutic gene delivery strategy, as it achieves efficient protein overexpression in vivo and has a desirable safety profile. However, mRNA's short cytoplasmic half-life limits its utility to therapeutic applications amenable to repeated dosing or short-term overexpression. Here, we describe a biomaterial that enables a durable in vivo response to a single mRNA dose via an "overexpress and sequester" mechanism, whereby mRNA-transfected cells locally overexpress a growth factor that is then sequestered within the biomaterial to sustain the biologic response over time. In a murine diabetic wound model, this strategy demonstrated improved wound healing compared to delivery of a single mRNA dose alone or recombinant protein. In addition, codelivery of anti-inflammatory proteins using this biomaterial eliminated the need for mRNA chemical modification for in vivo therapeutic efficacy. The results support an approach that may be broadly applicable for single-dose delivery of mRNA without chemical modification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.